Journal
CURRENT ONCOLOGY
Volume 25, Issue -, Pages S142-S150Publisher
MULTIMED INC
DOI: 10.3747/co.25.3954
Keywords
Breast cancer; triple-negative breast cancer
Categories
Funding
- Amgen
- Eisai
- AstraZeneca
- Novartis
- Pfizer
- Roche
- Genomic Health
- Shire
Ask authors/readers for more resources
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings. In this review, we discuss evidence for the potential benefit of neoadjuvant platinum-based chemotherapy, adjuvant combination chemotherapy with weekly paclitaxel, and BRCA mutation-directed therapy in the metastatic setting. The role for adjuvant capecitabine in patients who do not achieve a pathologic complete response with neoadjuvant chemotherapy is reviewed. Future directions and data concerning novel targeted agents are reviewed, including the most recent data on parp [poly (ADP-ribose) polymerase] inhibitors, antiandrogen agents, and immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available